Steven-Johnson Syndrome (SJS) in a Multiple Myeloma patient treated with lenalidomide and low dose dexamethasone regimen: a rare Case Report

  • Dr Lohit kumar Kalita Assistant Professor, Department of Oncology, Gauhati Medical College & Hospital, Guwahati, Assam, India
  • Dr Chayanika Kalita Assistant Professor, Department of Dermatology, Gauhati Medical College & Hospital, Guwahati, Assam, India
  • Dr Pabitra Kamar Gogoi Prof.& HOD, (Rtd), Department of Clinical Hematology, Gauhati Medical College & Hospital, Guwahati, Assam, India
  • Dr Umesh Ch. Sarma Vice-Chanchellor, Srimanta Sankadeva University of Health sciences, Narakasur Hill Top, Guwahati , Assam, India
DOI: https://doi.org/10.17511/ijmrr.2015.i3.063
Keywords: Lenalidomide, Immunomodulatory Drugs, Multiple Myeloma, Adverse Cutaneous Reactions, Stevens-Johnson Syndrome

Abstract

Lenalidomide is an immunomodulatory drug (IMiD), a derivative of thalidomide used in the treatment of multiple myeloma. Stevens-Johnson syndrome (SJS) is a rare but life-threatening cutaneous adverse reaction, at a rate of 1.1 to 7.1 cases per million person-years, mortality rate between 1% to 3% and 10% to 70% when it is associated with TIN. Very few cases of Lenalidomide induced SJS has been reported. We describe a case of Stevens-Johnson syndrome induced by induction therapy lenalidomide-low dose Dexamethasone regimen in a 56 year-old male who underwent induction therapy for multiple myeloma.

Downloads

Download data is not yet available.

References

1. Letko E1, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of the literature. Ann Allergy Asthma Immunol. 2005 Apr;94(4):419-36; quiz 436-8, 456. [PubMed]

2. Roujeau JC: Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 24(11):726-729, 1997.

3. Svigguni H, Davis M, Rajkumar V, Dispenzieri A. Dermatologicadverse effects of lenalidomide therapy for amyloidosis andmultiple myeloma. Arch Dermatol. 2006 Oct;142(10):1298-302. [PubMed]

4. Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis JB. Erythema multiforme/Stevens---Johnson syndrome/toxic epi-dermal necrolysis in lenalidomide-treated patients. J Clin Oncol. 2009 Jan 1;27(1):156-7. doi: 10.1200/JCO.2008.20.3737. Epub 2008 Dec 1.

5. Allegra A, Alonci A, Penna G, Russo S, Gerace D, Greve B, et al.Stevens-Johnson syndrome after lenalidomide therapy for mul-tiple myeloma: a case report and a review of treatment options.Hematol Oncol. 2012;30:41---5.

6. Chavakis E, Dernbach E, Hermann C, Mondorf UF, Zeiher AM,Dimmeler S. Oxidized LDL inhibits vascular endothelial growthfactor-induced endothelial cell migration by an inhibitory effecton the Akt/endothelial nitric oxide synthase pathway. Circula-tion. 2001;103:2102 - 7.
CITATION
DOI: 10.17511/ijmrr.2015.i3.063
Published: 2015-04-30
How to Cite
1.
kumar Kalita L, Kalita C, Kamar Gogoi P, Ch. Sarma U. Steven-Johnson Syndrome (SJS) in a Multiple Myeloma patient treated with lenalidomide and low dose dexamethasone regimen: a rare Case Report. Int J Med Res Rev [Internet]. 2015Apr.30 [cited 2024Jul.3];3(3):353-5. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/239
Issue
Vol 3 No 3 (2015): APRIL
Section
Case Report